🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06431373
Active, not recruiting Phase 3

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373 · tracked via the Priya Life Science UK tracker
Sponsor
Priovant Therapeutics, Inc.
Phase
Phase 3
Started
2024-09-11
Last updated
2026-01-12

Condition(s) studied

Uveitis, PosteriorUveitis, IntermediateUveitis

Investigational drug(s) / intervention(s)

Brepocitinib PO QDPlacebo PO QD

Brepocitinib PO QD: Brepocitinib PO QD

Placebo PO QD: Placebo PO QD

Study summary

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Adult subjects (18-75 years old) * Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis) * Active uveitic disease in at least 1 eye * Weight \> 40 kg with a body mass index ≤ 40 kg/m2 Exclusion Criteria: Has confirmed or suspected current diagnosis of infectious uveitis History of or have: 1. Lymphoproliferative disorder 2. active malignancy 3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.) 4. thrombosis or cerebrovascular ischemic event disease within the last 12 months 5. a high risk for herpes zoster reactivation 6. active or recent infections

Primary outcome measure(s)

Trial sites (107)

FacilityCityRegionStatus
Clinical Trial Site Phoenix Arizona
Clinical Trial Site Phoenix Arizona
Clinical Trial Site Bakersfield California
Clinical Trial Site Beverly Hills California
Clinical Trial Site Fullerton California
Clinical Trial Site Irvine California
Clinical Trial Site La Jolla California
Clinical Trial Site Los Angeles California
Clinical Trial Site Los Angeles California
Clinical Trial Site Modesto California
Clinical Trial Site Sacramento California
Clinical Trial Site Aurora Colorado
Clinical Trial Site Denver Colorado
Clinical Trial Site Fort Lauderdale Florida
Clinical Trial Site St. Petersburg Florida
Clinical Trial Site Chicago Illinois
Clinical Trial Site Oak Park Illinois
Clinical Trial Site Carmel Indiana
Clinical Trial Site Prairie Village Kansas
Clinical Trial Site Baltimore Maryland
Clinical Trial Site Boston Massachusetts
Clinical Trial Site Waltham Massachusetts
Clinical Trial Site Ann Arbor Michigan
Clinical Trial Site Detroit Michigan
Clinical Trial Site Detroit Michigan
Clinical Trial Site Minneapolis Minnesota
Clinical Trial Site Rochester Minnesota
Clinical Trial Site St Louis Missouri
Clinical Trial Site Omaha Nebraska
Clinical Trial Site Palisades Park New Jersey
NYU Langone Health New York New York
Clinical Trial Site Rochester New York
Clinical Trial Site Durham North Carolina
Clinical Trial Site Winston-Salem North Carolina
Clinical Trial Site Cleveland Ohio
Clinical Trial Site Cleveland Ohio
Clinical Trial Site Columbus Ohio
Clinical Trial Site Portland Oregon
Clinical Trial Site Portland Oregon
Clinical Trial Site Erie Pennsylvania

+ 67 more sites — see the full list on the official registry below.

More Priovant Therapeutics, Inc. trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06431373 on ClinicalTrials.gov ↗ ← All trials in the UK